Glumetinib
- Generic Name
- Glumetinib
- Drug Type
- Small Molecule
- Chemical Formula
- C21H17N9O2S
- CAS Number
- 1642581-63-2
- Unique Ingredient Identifier
- 7JTT036WGX
- Background
Glumetinib is under investigation in clinical trial NCT04270591 (Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced C-met-positive Non-small Cell Lung Cancer).
- Indication
用于具有间质-上皮转化因子（MET）外显子14（MET-14）跳变的局部晚期或转移性非小细胞肺癌（NSCLC）的治疗。
Pipeline Analysis Reveals 20+ Drug Candidates for c-MET+ NSCLC Treatment
• DelveInsight's latest pipeline report identifies over 20 pharmaceutical companies actively developing treatments for c-MET-positive Non-Small Cell Lung Cancer, with multiple promising candidates in various clinical stages.
• AbbVie's telisotuzumab vedotin enters Phase 3 trials in January 2025, comparing its efficacy against docetaxel in previously treated c-Met overexpressing NSCLC patients.
• Key players including AbbVie, Janssen, and Beijing Pearl Biotechnology are advancing novel therapeutic approaches, from bispecific antibodies to targeted small molecules for c-MET NSCLC treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath